Sign In
Buy AORT
$20.58
+0.160 (+0.784%)
At Close: Jun 03, 2026
Artivion (AORT) Tops Q2 Earnings and Revenue Estimates
07:06pm, Thursday, 07'th Aug 2025
Artivion (AORT) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.07 per share a year ago.
Artivion (AORT) Q2 EPS Jumps 243%
05:23pm, Thursday, 07'th Aug 2025
Artivion (AORT) Q2 EPS Jumps 243%
Artivion Reports Second Quarter 2025 Financial Results
04:05pm, Thursday, 07'th Aug 2025
Second Quarter Highlights: Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a GAAP basis and 14% on a non-GAAP
Artivion to Participate in Upcoming Investor Conferences
04:10pm, Wednesday, 30'th Jul 2025
ATLANTA , July 30, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results
04:10pm, Thursday, 24'th Jul 2025
ATLANTA , July 24, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2025 financial resu
NEWTOWN, Pa., July 13, 2025 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at Artivion, Inc. (“Artivion”).
Artivion to Participate in Upcoming Investor Conferences
04:10pm, Tuesday, 03'rd Jun 2025
ATLANTA , June 3, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming i
ATLANTA , May 28, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of transactions related to pr
Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock
04:01pm, Wednesday, 14'th May 2025
ATLANTA , May 14, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, privately
Artivion, Inc. (AORT) Q1 2025 Earnings Call Transcript
10:37pm, Monday, 05'th May 2025
Artivion, Inc. (NYSE:AORT ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief F
Artivion (AORT) Lags Q1 Earnings Estimates
06:51pm, Monday, 05'th May 2025
Artivion (AORT) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.06 per share a year ago.
Artivion Reports First Quarter 2025 Financial Results
04:05pm, Monday, 05'th May 2025
First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP const
30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal ATLANTA , May 5, 2025 /PRNewswire/ -- Artivion
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results
04:10pm, Monday, 21'st Apr 2025
ATLANTA , April 21, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2025 financial resul
Strength Seen in Artivion (AORT): Can Its 7.9% Jump Turn into More Strength?
10:11am, Thursday, 10'th Apr 2025
Artivion (AORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
